Navigation Links
Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt
Date:5/22/2013

ugmentationstherapie mit einem Alpha-1-Proteinasehemmer (Alpha-1-PI) bei Lungenerkrankungen und dem Verlauf von Emphysemen bei Alpha-1-Antitrypsinmangel wurde noch nicht in randomisierten, kontrollierten klinischen Studien nachgewiesen. PROLASTIN-C ist nicht als Therapie für Lungenerkrankungen in Patienten vorgesehen, bei denen kein schwerer Alpha-1-PI-Mangel festgestellt wurde.

PROLASTIN-C kann Spuren von IgA enthalten. Bei Patienten, bei denen das Vorhandensein IgA-Antikörpern festgestellt wurde, die bei selektivem oder schwerem IgA-Mangel vorhanden sein können, besteht ein größeres Risiko für potenziell schwere Überempfindlichkeits- und anaphylaktische Reaktionen. PROLASTIN-C ist bei Patienten mit IgA-Antikörpern kontraindiziert.

Die meisten arzneimittelbedingten Nebenwirkungen bei den klinischen Studien waren bei ≥1 % der Probanden Frösteln, Unwohlsein, Kopfschmerz, Ausschlag, Hitzewallung und Pruritus. Die schwerste, bei der klinischen Studie von PROLASTIN-C beobachtete Komplikation war ein Ausschlag im Bauchbereich und an den Extremitäten bei einem Probanden.

PROLASTIN-C wird aus menschlichem Plasma hergestellt. Bei Produkten aus menschlichem Plasma kann das Risiko einer Übertragung von Infektionserregern bestehen, z.B. Viren und, zumindest theoretisch, des Erregers der Creutzfeldt-Jakob-Krankheit (CJD).

Die vollständigen Informationen zur Verschreibung finden Sie auf http://www.talecris-pi.info/inserts/PROLASTIN-C.pdf

Sie werden ersucht, negative Nebenwirkungen von rezeptpflichtigen Medikamenten bei der FDA zu melden. Besuchen Sie hierzu www.fda.gov/medwatch oder wenden Sie sich telefonisch an 1-800-FDA-1088.


'/>"/>
SOURCE Grifols
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. RNL BIO Co. Ltd. stellt IND-Antrag, um klinische Phase-II-Studie des RNL-JointStem gegen Arthrose in den Vereinigten Staaten einzuleiten
2. Acutus Medical, Inc. erprobt erstmals seinen Echtzeit-3D-Bildgebungskatheter von CT/MRI-Qualität in einer klinischen Studie am Menschen
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Eine in European Radiology veröffentlichte Studie untermauert den Nutzen von Hologics Brust-Tomosynthese beim Screening bei Verfahren mit Zweitbefundung
6. Neuartige Krebsimmuntherapie für den Beginn klinischer Studien bereit
7. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
8. Studies Published in Pain Medicine Demonstrate Effectiveness of Minimally-Invasive Cooled Radiofrequency Treatment for Low Back Pain
9. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
10. Managing Bioequivalence Studies to Optimize Cost, Quality, and Outsourcing of Generics Manufacturing
11. Studies Show Pharma has a Strong Opportunity to Market to New Decision Makers via Digital Channels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011 Varian Medical Systems (NYSE: VAR ... information system has received Surescripts® e-prescribing certification for new ... ARIA system to manage radiation therapy treatments will be ... the Surescripts network. "E-Prescribing allows the ...
... Mont., May 5, 2011 Bacterin International Holdings, ... a creator and developer of revolutionary bone graft material ... it is commencing distribution of the Company,s third human ... Bacterin,s hMatrix® is an acellular matrix processed ...
Cached Medicine Technology:The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 2The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 3Bacterin International Holdings Launches Third Biologic Scaffold 2Bacterin International Holdings Launches Third Biologic Scaffold 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... other particles tracked indoors can be harmful, researchers warn , ... that coats your furniture and floors comes from outdoors and ... The researchers developed a computer model that can track the ... found that more than 60 percent of household dust originates ...
... ... featured Keynote at this year,s Molecular Medicine Tri-Conference, is the inspiration for a new ... ... 11, 2009 -- Cambridge Healthtech Institute,s (CHI) flagship event, the Molecular Medicine Tri-Conference (February ...
... WellPoint,s affiliated Life and Disability Companies are pleased to announce ... help new mothers adjust to their newborn baby and return ... available to all new and in-force short term disability plans ... have access to Newborn and Parenting Resources once their baby ...
... Internationally recognised refractive ... talk the audience through each step of the procedure as the laser treatment is being ... ... procedure in a free live broadcast. He will talk the audience through each step of ...
... ... ... HEALTHeCAREERS , North America’s premier healthcare Network, is advertising more than 14,000 job ... to be one of the few bright spots in the North American job market. ...
... Vivacare.com ... honor of Epilepsy Awareness Month. , ... Berkeley, CA (PRWEB) Nov 9, 2009 -- Vivacare provides ... in honor of Epilepsy Awareness Month. , , , , ,Leading neurologists, such as ...
Cached Medicine News:Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:WellPoint's Affiliated Life and Disability Companies Offer Newborn and Parenting Resources to Ease New Mothers' Transition Back to Work After Maternity Leave 2Health News:Eye Surgeon Broadcasts own Surgery 2Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Neurologists Receive New Patient Education Resources from Vivacare for Epilepsy Awareness Month 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
... Conserver., ,Offers an average 5:1 increase in ... the use of a standard cannula. , ... cylinders offers ambulatory oxygen patients a superior alternative ... a 2-year warranty. , ...
Medicine Products: